Navigation Links
Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
Date:3/12/2013

VANCOUVER, British Columbia, March 12, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp (OTC PINK: ATTBF) (CNSX: FLU) today announced that it has provided $10,000 sponsorship for the cannabis (cannabis sp.) monograph and therapeutic compendium currently under development by the American Herbal Pharmacopoeia (AHP).

The monograph, scheduled for release in Spring 2013, will provide industry with a variety of scientifically valid analytical methods suitable for use in the identification, purity, and quality assessment of cannabis and its crude products.

Health Canada has recently proposed changes to the Canada's Marijuana Medical Access Program that aims to treat marijuana as it does any prescribed drug, allowing for legal commercial production for those who meet specific requirements.

"This generous sponsorship from Abattis Bioceuticals will facilitate the completion of this important and timely monograph," said Roy Upton , executive director of AHP.  "There is a critical need for quality controls to be put in place in the cannabis industry to ensure valid and appropriate testing methodologies, and the AHP monograph will help to create greater transparency and establish standard methods of analysis."

"We are extremely proud to support the development of this monograph by AHP," said Mr. Michael Withrow , Abattis' chief executive officer. He went on to say, "There is a strong need for the development of transparent standards for cannabis and its products and an incredible need for objective and critical review of the therapeutic and safety data on cannabis, especially now as the laws are being changed to allow for multiple uses of this misunderstood botanical. The world needs standards for Cannabis and the many phytochemicals that come from it so lawmakers can properly categorize them and so formulators can legally apply the compounds in appropriate products that help those who are suffering from various chronic diseases."

About Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp., based in Langley, B.C., is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of growing, producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in the pharmaceuticals, nutraceuticals, cosmetics, and animal nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high-growth areas of functional foods and dietary supplements business. For more information, visit the company's website at www.abattis.com.

About the American Herbal Pharmacopoeia

The American Herbal Pharmacopoeia is a non-profit 501C(3), California-based research organization with a mission to promote the responsible use of herbal products and herbal medicines through the production of critically reviewed monographs that outline the quality control criteria needed for ensuring the identity, purity, and quality of botanical raw materials. Founded in 1995, AHP has monographs on 35 different botanicals. For more information, visit AHP's website, http://www.herbal-ahp.org/index.html.

ON BEHALF OF THE BOARD

" Michael Withrow "
Michael Withrow , President & CEO

Mr. Mike Withrow

778-896-6536

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements.  These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances.  In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control.  There can be no assurance that any forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements.  Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or to revise them to reflect the occurrence of future unanticipated events.


'/>"/>
SOURCE Abattis Bioceuticals Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
2. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
4. NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
5. Medical Alarm Concepts Provides Investor Update - Signs Deal with Health Care Insurance Provider for Medical Alarms
6. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
7. Compass Diversified Holdings Provides Shareholders with 2012 Tax Information
8. Volcano Corporation Provides Additional Guidance For 2013
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
10. AcelRx Pharmaceuticals Provides Clinical Trial Updates
11. Masimo Reports Fourth Quarter and Full Year 2012 Financial Results; Provides 2013 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):